NO20063239L - Injiserbare mikropartikkelpreparater - Google Patents
Injiserbare mikropartikkelpreparaterInfo
- Publication number
- NO20063239L NO20063239L NO20063239A NO20063239A NO20063239L NO 20063239 L NO20063239 L NO 20063239L NO 20063239 A NO20063239 A NO 20063239A NO 20063239 A NO20063239 A NO 20063239A NO 20063239 L NO20063239 L NO 20063239L
- Authority
- NO
- Norway
- Prior art keywords
- partially
- opioid
- drug
- opioid antagonist
- opioid agonist
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000011859 microparticle Substances 0.000 title 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 239000003402 opiate agonist Substances 0.000 abstract 3
- 239000003401 opiate antagonist Substances 0.000 abstract 3
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 abstract 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 abstract 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 abstract 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 abstract 1
- 229960001736 buprenorphine Drugs 0.000 abstract 1
- 229960002069 diamorphine Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000010255 intramuscular injection Methods 0.000 abstract 1
- 239000007927 intramuscular injection Substances 0.000 abstract 1
- 229960001797 methadone Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Det tilveiebringes en injiserbar saktefiigjørende, delvis opioid agonist- eller opioid antagonistformulering omfattende en delvis opioid agonist eller opioid antagonist i en poly(D,L-laktid)-eksipiens med en liten mengde gjenværende etylacetat. Ved inttamuskulær injeksjon av preparatet fi-igjøres en delvis opioid agonist eller opioid antagonist på en konttollert måte over et utvidet tidsrom. Preparatet kan anvendes ved behandling av heroinavhengige og alkoholikere for å redusere forbruket av det misbrukte stoffet. Av spesieU interesse er medikamentene buprenorfin, metadon og nalttekson.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15111299P | 1999-08-27 | 1999-08-27 | |
PCT/US2000/023390 WO2001015699A1 (en) | 1999-08-27 | 2000-08-25 | Injectable buprenorphine microparticle compositions and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20063239L true NO20063239L (no) | 2002-04-03 |
Family
ID=22537367
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20020924A NO322650B1 (no) | 1999-08-27 | 2002-02-26 | Injiserbare buprenorfinmikropartikkelpreparater og deres anvendelse |
NO20063239A NO20063239L (no) | 1999-08-27 | 2006-07-12 | Injiserbare mikropartikkelpreparater |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20020924A NO322650B1 (no) | 1999-08-27 | 2002-02-26 | Injiserbare buprenorfinmikropartikkelpreparater og deres anvendelse |
Country Status (24)
Country | Link |
---|---|
US (2) | US6495155B1 (no) |
EP (1) | EP1212061B1 (no) |
JP (1) | JP4913298B2 (no) |
KR (1) | KR100730440B1 (no) |
CN (2) | CN1248689C (no) |
AT (1) | ATE280579T1 (no) |
AU (1) | AU765496C (no) |
BR (1) | BR0013650A (no) |
CA (1) | CA2382577C (no) |
CY (1) | CY1106043T1 (no) |
CZ (1) | CZ2002728A3 (no) |
DE (1) | DE60015370T2 (no) |
EA (1) | EA009080B1 (no) |
ES (1) | ES2230154T3 (no) |
HK (1) | HK1046858B (no) |
HU (1) | HUP0203613A3 (no) |
IL (2) | IL148343A0 (no) |
MX (1) | MXPA02002105A (no) |
NO (2) | NO322650B1 (no) |
NZ (1) | NZ517997A (no) |
PL (1) | PL198334B1 (no) |
PT (1) | PT1212061E (no) |
RO (1) | RO121631B1 (no) |
WO (1) | WO2001015699A1 (no) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ2002728A3 (cs) * | 1999-08-27 | 2002-08-14 | Southern Research Institute | Prostředek ve formě mikročástic obsahující buprenorfin, léková forma a pouľití |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
AU2002315505B2 (en) * | 2001-06-29 | 2008-01-17 | Medgraft Microtech, Inc. | Biodegradable injectable implants and related methods of manufacture and use |
WO2003002071A2 (en) * | 2001-06-29 | 2003-01-09 | Lewandowski Leon J | Individualized addiction cessation therapy |
ATE376832T1 (de) | 2001-07-06 | 2007-11-15 | Penwest Pharmaceuticals Co | Verzögert freisetzende formulierungen von oxymorphon |
US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
CN1268338C (zh) | 2001-07-06 | 2006-08-09 | 恩德制药公司 | 用作止痛剂的6-羟基羟吗啡酮的口服给药 |
CA2459976A1 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
US7462366B2 (en) | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
US7041320B1 (en) * | 2002-05-31 | 2006-05-09 | Biotek, Inc. | High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence |
US7736665B2 (en) | 2002-05-31 | 2010-06-15 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of buprenorphine |
US7842377B2 (en) * | 2003-08-08 | 2010-11-30 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
US8012454B2 (en) | 2002-08-30 | 2011-09-06 | Boston Scientific Scimed, Inc. | Embolization |
US7883490B2 (en) | 2002-10-23 | 2011-02-08 | Boston Scientific Scimed, Inc. | Mixing and delivery of therapeutic compositions |
WO2004078178A1 (en) * | 2003-03-03 | 2004-09-16 | Markus Heilig | Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use |
ES2359977T3 (es) | 2003-03-31 | 2011-05-30 | Titan Pharmaceuticals, Inc. | Dispositivo polimérico implantable para liberación sostenida de agonista de dopamina. |
US7976823B2 (en) | 2003-08-29 | 2011-07-12 | Boston Scientific Scimed, Inc. | Ferromagnetic particles and methods |
US7901770B2 (en) | 2003-11-04 | 2011-03-08 | Boston Scientific Scimed, Inc. | Embolic compositions |
US7736671B2 (en) | 2004-03-02 | 2010-06-15 | Boston Scientific Scimed, Inc. | Embolization |
US8173176B2 (en) | 2004-03-30 | 2012-05-08 | Boston Scientific Scimed, Inc. | Embolization |
US7919499B2 (en) * | 2004-04-22 | 2011-04-05 | Alkermes, Inc. | Naltrexone long acting formulations and methods of use |
FR2869801B1 (fr) * | 2004-05-05 | 2008-09-12 | Ethypharm Sa | Procede de preparation de compositions a liberation prolongee et utilisation de ces compositions pour le traitement des affections chroniques du systeme nerveux central (snc) |
US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
CN101076314A (zh) * | 2004-08-04 | 2007-11-21 | 克里纽沃药物有限公司 | 在对象体内诱导黑素生成的方法 |
US7727555B2 (en) | 2005-03-02 | 2010-06-01 | Boston Scientific Scimed, Inc. | Particles |
US7858183B2 (en) | 2005-03-02 | 2010-12-28 | Boston Scientific Scimed, Inc. | Particles |
US7963287B2 (en) | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
US20070141160A1 (en) * | 2005-12-15 | 2007-06-21 | Brown Laura J | Method of treatment for osteoarthritis by local intra-articular injection of microparticles |
US7947368B2 (en) | 2005-12-21 | 2011-05-24 | Boston Scientific Scimed, Inc. | Block copolymer particles |
WO2008106571A2 (en) * | 2007-02-28 | 2008-09-04 | Abbott Laboratories | Sustained release parenteral formulations of buprenorphine |
EP2197429B9 (en) | 2007-09-03 | 2016-10-26 | Nanotherapeutics, Inc. | Particulate compositions for delivery of poorly soluble drugs |
EP2222281B1 (en) * | 2007-12-20 | 2018-12-05 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
US9757343B2 (en) * | 2008-09-24 | 2017-09-12 | Evonik Röhm Gmbh | PH-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol |
CN104984343B (zh) * | 2008-09-24 | 2019-04-02 | 赢创罗姆有限公司 | 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物 |
PL2326313T3 (pl) | 2008-09-24 | 2015-08-31 | Evonik Roehm Gmbh | Kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu dla nieopioidów z odpornością przed wpływem etanolu |
US20100268191A1 (en) * | 2009-04-21 | 2010-10-21 | Medtronic Vascular, Inc. | Drug Delivery Catheter using Frangible Microcapsules and Delivery Method |
US9125867B2 (en) | 2010-02-24 | 2015-09-08 | Invincible Biotechnology | Diversion- and/or abuse-resistant compositions and methods for making the same |
GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
US9272044B2 (en) * | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
WO2013126552A1 (en) | 2012-02-21 | 2013-08-29 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
CA2868413C (en) | 2012-04-17 | 2021-07-20 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
CN102836131A (zh) * | 2012-09-28 | 2012-12-26 | 山东大学 | 丁丙诺啡皮下注射用缓释微球制剂及其制备方法 |
US9393211B2 (en) | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
US9636308B2 (en) | 2013-03-15 | 2017-05-02 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
JP6135292B2 (ja) * | 2013-05-10 | 2017-05-31 | ニプロ株式会社 | マイクロカプセル製剤の製造方法 |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
US11000520B2 (en) * | 2014-11-07 | 2021-05-11 | Indivior Uk Limited | Buprenorphine dosing regimens |
WO2017147285A1 (en) | 2016-02-23 | 2017-08-31 | Biodelivery Sciences International, Inc. | Sustained release buprenorphine microspheres (srbm) and methods of use thereof |
FI3512518T3 (fi) | 2016-09-13 | 2023-01-31 | Hitaasti vapautuvia buprenorfiiniformulaatioita | |
US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
CN114401746A (zh) * | 2019-08-12 | 2022-04-26 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 包括鸦片拮抗剂组合的药学组合物及复合材料及其使用方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4530840A (en) * | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4568559A (en) | 1984-02-06 | 1986-02-04 | Biotek, Inc. | Composite core coated microparticles and process of preparing same |
US4623588A (en) | 1984-02-06 | 1986-11-18 | Biotek, Inc. | Controlled release composite core coated microparticles |
GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US5143661A (en) * | 1987-05-26 | 1992-09-01 | American Cyanamid Company | Silicone-hardened pharmaceutical microcapsules |
FR2618674B1 (fr) | 1987-07-30 | 1990-06-15 | Ire Celltarg Sa | Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation |
GB8728294D0 (en) | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
US4902515A (en) * | 1988-04-28 | 1990-02-20 | E. I. Dupont De Nemours And Company | Polylactide compositions |
US5702716A (en) * | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
ATE133087T1 (de) | 1989-05-04 | 1996-02-15 | Southern Res Inst | Einkapselungsverfahren |
US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
AU2605592A (en) * | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US5633000A (en) | 1994-06-23 | 1997-05-27 | Axxia Technologies | Subcutaneous implant |
US5716631A (en) | 1995-09-29 | 1998-02-10 | Rdn Therapeutics Inc. | Long acting narcotic analgesics and antagonists |
US5919473A (en) * | 1997-05-12 | 1999-07-06 | Elkhoury; George F. | Methods and devices for delivering opioid analgesics to wounds via a subdermal implant |
CZ2002728A3 (cs) * | 1999-08-27 | 2002-08-14 | Southern Research Institute | Prostředek ve formě mikročástic obsahující buprenorfin, léková forma a pouľití |
-
2000
- 2000-08-25 CZ CZ2002728A patent/CZ2002728A3/cs unknown
- 2000-08-25 CN CNB008147280A patent/CN1248689C/zh not_active Expired - Fee Related
- 2000-08-25 EA EA200200295A patent/EA009080B1/ru not_active IP Right Cessation
- 2000-08-25 RO ROA200200190A patent/RO121631B1/ro unknown
- 2000-08-25 KR KR1020027002567A patent/KR100730440B1/ko not_active IP Right Cessation
- 2000-08-25 PL PL354977A patent/PL198334B1/pl not_active IP Right Cessation
- 2000-08-25 US US09/648,255 patent/US6495155B1/en not_active Expired - Lifetime
- 2000-08-25 EP EP20000959422 patent/EP1212061B1/en not_active Expired - Lifetime
- 2000-08-25 CN CNB2005100927174A patent/CN100387228C/zh not_active Expired - Fee Related
- 2000-08-25 HU HU0203613A patent/HUP0203613A3/hu unknown
- 2000-08-25 PT PT00959422T patent/PT1212061E/pt unknown
- 2000-08-25 JP JP2001519913A patent/JP4913298B2/ja not_active Expired - Lifetime
- 2000-08-25 IL IL14834300A patent/IL148343A0/xx active IP Right Grant
- 2000-08-25 AT AT00959422T patent/ATE280579T1/de not_active IP Right Cessation
- 2000-08-25 BR BR0013650-6A patent/BR0013650A/pt not_active Application Discontinuation
- 2000-08-25 WO PCT/US2000/023390 patent/WO2001015699A1/en active IP Right Grant
- 2000-08-25 MX MXPA02002105A patent/MXPA02002105A/es active IP Right Grant
- 2000-08-25 ES ES00959422T patent/ES2230154T3/es not_active Expired - Lifetime
- 2000-08-25 NZ NZ517997A patent/NZ517997A/xx unknown
- 2000-08-25 DE DE60015370T patent/DE60015370T2/de not_active Expired - Lifetime
- 2000-08-25 AU AU70751/00A patent/AU765496C/en not_active Ceased
- 2000-08-25 CA CA002382577A patent/CA2382577C/en not_active Expired - Lifetime
-
2002
- 2002-02-24 IL IL148343A patent/IL148343A/en not_active IP Right Cessation
- 2002-02-26 NO NO20020924A patent/NO322650B1/no not_active IP Right Cessation
- 2002-11-21 HK HK02108436.3A patent/HK1046858B/zh not_active IP Right Cessation
- 2002-12-17 US US10/324,062 patent/US7473431B2/en not_active Expired - Lifetime
-
2005
- 2005-01-14 CY CY20051100081T patent/CY1106043T1/el unknown
-
2006
- 2006-07-12 NO NO20063239A patent/NO20063239L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20063239L (no) | Injiserbare mikropartikkelpreparater | |
NO20014896L (no) | Injiserbare naltrexonmikrosfaerepreparater og deres anvendelse ved redusering av heroin- og alkoholforbruk | |
US6004970A (en) | Smoking cessation treatments using naltrexone and related compounds | |
TR200103302T2 (tr) | Diamorfin etkin maddeli farmasötik preparat | |
Bhargava | Antagonism of ketamine-induced anesthesia and hypothermia by thyrotropin releasing hormone and cyclo (His-Pro) | |
EP1555023A3 (en) | Injectable buprenorphine microparticle compositions and their use | |
Shu et al. | The comparison of effects of processed Aconiti tuber, U50488H and MK-801 on the antinociceptive tolerance to morphine | |
Kamei et al. | Antinociceptive effect of lipopolysaccharide from Pantoea agglomerans on streptozotocin-induced diabetic mice | |
Streel et al. | Interference with withdrawal signs of naloxone-induced opiate withdrawal under anesthesia is anesthetic-specific in opiate-dependent rats | |
AU9221898A (en) | Pharmaceutical coating composition and method of use | |
Wright Jr et al. | Comparative effects of dextromethorphan and dextrorphan on nicotine discrimination in rats | |
Földes et al. | Effects of methysergide, bromocriptine and naloxone on prolactin, growth hormone and TSH release induced by d-Met 2, Pro 5-enkephalinamide in man | |
Ji et al. | Endothelin B receptors exert antipruritic effects via peripheral κ-opioid receptors | |
Tazi et al. | Effects of naloxone, β-endorphin and ACTH on acquisition of schedule-induced polydipsia | |
Eggers et al. | Tramadol hydrochloride--not just another opioid agonist. | |
Vanecek et al. | Repeated treatment with high doses of morphine produces comparable tolerance to low-and high-dose discriminative stimulus effects of morphine. | |
OELTGEN | Characterization and utilization of opiate-like hibernation factors(Report, 15 Jul. 1992- 15 Dec. 1993) | |
Hong et al. | Bidirectional cross-tolerance between methadone (mu)—and ethylketocyclazocine (kappa)—tolerant rats | |
Pingping et al. | Study on Stability of Four Kinds of Cardiovascular Ready-prepared Chinese Medicine in Betahistine Hydrochloride Sodium Chloride Injection | |
UA29558C2 (uk) | Препарат для лікування бронхіальної астми " еуфілін-н 200" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |